Percutaneous Coronary Intervention Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Acute coronary syndrome revascularization strategies with multi-vessel coronary artery disease
In acute coronary syndromes (ACS), revascularization is the standard of care. However, trials comparing contemporary coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are limited. Optimal revascularization in patients with multi-vessel coronary artery disease (MV-CAD) presenting with ACS is unclear. This is a multi-centred, retrospective observational study from a large, hospital system in the United States. We abstracted data on patients with MV-CAD and ACS from 2018 to 2022 who underwent revascularization with PCI, CABG or medically managed (MM). (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 4, 2024 Category: Cardiology Authors: R. Jay Widmer, Kendall Hammonds, Timothy Mixon, Jose Emilio Exaire, Christopher Douglas Chiles, Giuseppe Tavilla, Molly I. Szerlip, J. Michael DiMaio Source Type: research

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)
AbstractIntroductionIn patients with type 2 diabetes (T2D), treatment with sodium –glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.ObjectivesThe effect of luseogliflozin on myocardial flow reserve (MFR) in patients with T2D (LUCENT-J) study aims to examine the effects of SGLT2 inhibitors on myocardial perfusion.MethodsThe LUCENT-J study is a prospective, single-center, randomized, two-arm, parallel-group, open-label...
Source: Diabetes Therapy - April 4, 2024 Category: Endocrinology Source Type: research

One-Month Dual Antiplatelet Therapy Followed by P2Y < sub > 12 < /sub > Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation 　- The REIWA Region-Wide Registry
CONCLUSIONS: The REIWA region-wide registry suggests that 1-month DAPT followed by P2Y12inhibitor monotherapy is safe and feasible for Japanese patients with BP-DES.PMID:38569870 | DOI:10.1253/circj.CJ-24-0091 (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2024 Category: Cardiology Authors: Masaru Ishida Ryutaro Shimada Fumiaki Takahashi Masanobu Niiyama Takenori Ishisone Yuki Matsumoto Yuya Taguchi Takuya Osaki Osamu Nishiyama Hiroshi Endo Ryohei Sakamoto Kentaro Tanaka Yorihiko Koeda Takumi Kimura Iwao Goto Ryo Ninomiya Wataru Sasaki Tomon Source Type: research

Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area
CONCLUSIONS: Administration of crushed prasugrel may improve postprocedural TIMI 3 flow in STEMI patients with signs of a large myocardial area at risk on the ambulance ECG. The practice of crushing tablets of prasugrel loading dose might, therefore, represent a safe, fast and cost-effective strategy to improve myocardial reperfusion in this high-risk STEMI subgroup undergoing primary percutaneous coronary intervention.PMID:38562070 | PMC:PMC10979386 | DOI:10.4244/EIJ-D-23-00618 (Source: EuroIntervention)
Source: EuroIntervention - April 2, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Jeroen M Wilschut Rosanne F Vogel Jacob J Elscot Ronak Delewi Miguel E Lemmert Nancy W P L van der Waarden Rutger-Jan Nuis Valeria Paradies Dimitrios Alexopoulos Felix Zijlstra Gilles Montalescot Dominick J Angiolillo Mitchell W Krucoff Pieter C Smits Geo Source Type: research